Overview

• US medical device maker's Q2 revenue fell 14% yr/yr due to loss of major customers

• Q2 diluted EPS declined 10% yr/yr as new sales failed to offset lost business

• Company saw higher litigation costs and slight contraction in gross margin

Outlook

• Utah Medical Products projects 2026 sales to decline 10-13% compared to 2025

• Company expects 2026 litigation expenses to be less than $1.6 mln

• Company says substantial uncertainty remains regarding sales development for 2026

Result Drivers

• LOSS OF MAJOR CUSTOMERS - Co said lower sales were mainly due to lack of sales to its two previously largest customers, which accounted for most of the revenue decline

• SLOW NEW SALES - Sales to new biopharma OEM customers were slower to develop than expected, with only $211 in new sales in 1H 2026

• HIGHER LITIGATION COSTS - Increased litigation expenses contributed to lower operating income in Q2

Company press release: ID:nACSwrZ0ma

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Sales		$8.53 mln
Q2 EPS		$0.84
Q2 Net Income		$2.69 mln

Reuters Recommended Reads

• July 23 - Novocure Q2 revenue beats, lifts 2026 outlook

• July 23 - Thermo Fisher beats quarterly estimates as customer demand improves

• July 20 - Canada's Flexible Solutions Q2 revenue falls on one-time R&D drop, shipment delays

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.